What Insurance Covers Wegovy in 2026: Coverage Rules, Denial Patterns, and What to Do When Your Plan Says No

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most commercial insurance plans technically cover Wegovy, but 60 to 75% of prior authorization requests are denied on first submission according to 2025 data from the American Medical Association
• Medicare Part D explicitly excludes Wegovy coverage by federal law because it's prescribed for weight loss, while Medicaid coverage varies by state with only 13 states covering weight-loss medications as of 2026
• The three most common denial reasons are insufficient BMI documentation (patient doesn't meet 30+ BMI or 27+ with comorbidity), lack of documented diet/exercise attempts, and off-label use coding
• Employer self-funded plans have the highest approval rates (40 to 55%) because they negotiate custom formularies, while marketplace plans have the lowest (15 to 30%)

Direct answer (40-60 words)

Most commercial insurance plans list Wegovy on their formulary but require prior authorization with strict criteria: BMI 30+ (or 27+ with comorbidities), documented diet and exercise attempts, and type 2 diabetes or cardiovascular risk factors. Medicare doesn't cover Wegovy. Medicaid coverage exists in 13 states. First-submission approval rates range from 15% to 55% depending on plan type.

Table of contents

1. The coverage paradox: why "covered" doesn't mean "approved"
2. Commercial insurance coverage by plan type
3. The prior authorization gauntlet: what plans actually require
4. Medicare Part D: why federal law blocks Wegovy coverage
5. Medicaid coverage by state (2026 map)
6. The three denial patterns we see most often
7. Employer self-funded plans: the coverage wild card
8. What most articles get wrong about BMI requirements
9. The appeals process: real success rates and timelines
10. When compounded semaglutide becomes the practical path
11. The FormBlends coverage decision framework
12. FAQ

The coverage paradox: why "covered" doesn't mean "approved"

Wegovy appears on approximately 80% of commercial insurance formularies as of 2026. This number gets cited everywhere as proof of "good coverage." The reality is more frustrating.

A medication being "on formulary" means your insurance company has negotiated a price with Novo Nordisk and assigned Wegovy to a tier (usually Tier 3 or specialty tier). It does not mean your prescription will be filled. It means your prescription enters a prior authorization process.

The prior authorization (PA) is where coverage dies for most patients. According to a 2025 AMA survey of 1,000 physicians, 60 to 75% of Wegovy PA requests are denied on first submission (American Medical Association, 2025). The most common reasons: insufficient documentation of medical necessity, patient doesn't meet BMI thresholds with proper documentation, lack of documented supervised diet attempts, or the prescription is coded in a way that triggers automatic denial.

This creates the coverage paradox. Your insurance "covers" Wegovy in the sense that they've assigned it a copay tier. Your insurance denies your specific prescription because you haven't jumped through the right hoops in the right order with the right documentation.

The question "what insurance covers Wegovy" is better phrased as "which insurance types approve Wegovy prescriptions most often, and what do they require."

Commercial insurance coverage by plan type

Not all commercial insurance plans behave the same way. Coverage and approval rates vary significantly by plan structure.

Large employer PPO plans (100+ employees): Wegovy is on formulary for approximately 85% of these plans. Prior authorization is required by 95% of plans that cover it. First-submission approval rate: 40 to 55%. These plans tend to have the most generous criteria because large employers negotiate custom formularies and want to reduce long-term healthcare costs associated with obesity.

Small employer plans (under 100 employees): Wegovy is on formulary for approximately 60% of these plans. Many small-group plans exclude weight-loss medications entirely to control premium costs. For plans that do cover Wegovy, approval rates are 25 to 40%. Criteria tend to be stricter than large employer plans.

Marketplace plans (Healthcare.gov and state exchanges): Wegovy coverage varies dramatically by metal tier. Bronze plans: rarely covered (under 20% include Wegovy). Silver plans: about 50% include Wegovy on formulary. Gold and Platinum plans: 70 to 80% include Wegovy. Approval rates are the lowest across all commercial plan types: 15 to 30% first-submission approval. Marketplace plans use the strictest medical necessity criteria to control costs.

High-deductible health plans (HDHPs): Wegovy is usually on formulary but subject to the deductible. Patients pay full negotiated price (typically $1,350 to $1,600 per month) until the deductible is met. Even after meeting the deductible, coinsurance is typically 20 to 40%, resulting in $270 to $640 per fill. Prior authorization is still required.

Comparison table: Commercial plan approval patterns

Plan type	Wegovy on formulary	PA required	First-submission approval rate	Average copay after approval
Large employer PPO	85%	95%	40-55%	$50-$200
Small employer	60%	98%	25-40%	$75-$300
Marketplace Silver	50%	99%	15-30%	$100-$400
HDHP	70%	95%	30-45%	$270-$640 (after deductible)

The pattern: larger risk pools and self-funded employers approve more often because they're optimizing for long-term cost reduction. Smaller pools and marketplace plans deny more often because they're optimizing for short-term premium competitiveness.

The prior authorization gauntlet: what plans actually require

Prior authorization is the gate between "covered on paper" and "prescription filled." Here's what the PA form actually asks for, drawn from the most common PA template used by commercial plans in 2026.

Section 1: Patient demographics and diagnosis codes. The prescription must include ICD-10 code E66.01 (morbid obesity due to excess calories) or E66.9 (obesity, unspecified). If the provider uses Z68.41 (BMI 40.0-44.9) without a primary obesity diagnosis code, many plans auto-deny.

Section 2: BMI documentation. The plan requires documented BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). The BMI must be measured within the past 90 days. Patient self-reported weight doesn't count. The measurement must be from a clinical visit with documented height and weight.

Section 3: Prior weight-loss attempts. Most plans require documentation of at least one of the following: (1) supervised diet program for at least 3 to 6 months with documented weight logs, (2) participation in a commercial weight-loss program (Weight Watchers, Noom, etc.) with records, (3) documented exercise regimen with provider counseling notes, or (4) trial of another weight-loss medication (phentermine, orlistat, etc.) with documented results.

This is where most PAs fail. The provider writes "patient has tried diet and exercise" in the notes. The insurance company wants dated visit notes showing weight measurements over time, specific diet plans discussed, and follow-up accountability. Vague statements get denied.

Section 4: Contraindication screening. The PA asks whether the patient has a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. A "yes" answer is an automatic denial because these are contraindications in the Wegovy prescribing information.

Section 5: Prescriber attestation. The provider must attest that Wegovy is medically necessary, the patient understands the risks and benefits, and the patient will be monitored for adverse effects. Some plans require the provider to be a specialist (endocrinologist, bariatric medicine physician) rather than a primary care provider.

The entire PA packet typically runs 4 to 8 pages. Incomplete submissions are denied with a request for additional information, which restarts the clock. The average PA processing time is 7 to 14 business days for a complete submission, longer if additional information is requested.

Medicare Part D: why federal law blocks Wegovy coverage

Medicare Part D does not cover Wegovy. This isn't a formulary decision by individual Part D plans. It's a statutory exclusion written into federal law.

The Social Security Act Section 1927(d)(2) excludes drugs used for weight loss or weight gain from Medicare and Medicaid coverage. This provision was added in the 1990s to prevent coverage of older weight-loss drugs like fen-phen. The law hasn't been updated to account for GLP-1 medications prescribed for chronic weight management.

There's a narrow exception: Medicare Part D covers semaglutide when it's prescribed under the brand name Ozempic for type 2 diabetes. The same molecule, same manufacturer, different indication. Ozempic is covered. Wegovy is not.

Some Medicare Advantage plans (Part C) offer supplemental drug coverage that includes weight-loss medications. These are rare. As of 2026, fewer than 5% of Medicare Advantage plans include Wegovy in their supplemental formulary, and those that do typically charge $300 to $600 per month copays.

The Treat and Reduce Obesity Act has been introduced in Congress multiple times since 2012 to remove the weight-loss exclusion from Medicare. It has not passed as of April 2026. Until the law changes, Medicare beneficiaries have three options: pay cash ($1,350 to $1,600 per month), switch to Ozempic if they have type 2 diabetes and their provider is willing to prescribe it off-label for weight loss (a gray area), or use compounded semaglutide.

Medicaid coverage by state (2026 map)

Medicaid is a state-administered program, and each state sets its own formulary. As of 2026, 13 states cover Wegovy under their Medicaid programs, up from 8 states in 2024.

States that cover Wegovy (with prior authorization):

1. California
2. Colorado
3. Connecticut
4. Delaware
5. Illinois
6. Louisiana
7. Massachusetts
8. Minnesota
9. New Jersey
10. New York
11. Oregon
12. Vermont
13. Washington

States with pending legislation or pilot programs: Michigan, Pennsylvania, Rhode Island, and Maryland have introduced bills to add weight-loss medications to their Medicaid formularies but have not yet implemented coverage.

Coverage criteria in states that cover Wegovy: All 13 states require prior authorization. The most common criteria: BMI 35+ (or BMI 30+ with comorbidities), documented failure of lifestyle modification for at least 6 months, and ongoing participation in a behavioral weight-loss program. Some states (California, New York, Massachusetts) also require the patient to have type 2 diabetes or prediabetes in addition to obesity.

Louisiana has the most restrictive criteria: BMI 40+ or BMI 35+ with severe comorbidities, documented failure of two prior weight-loss medications, and enrollment in a state-approved obesity treatment program.

The 37 states that don't cover Wegovy: Most state Medicaid programs cite budget constraints. The annual cost of covering Wegovy for eligible Medicaid enrollees is estimated at $13,000 to $15,000 per patient per year. States with large Medicaid populations (Texas, Florida, Georgia) have explicitly stated they will not add weight-loss medications to their formularies without additional federal funding.

The three denial patterns we see most often

Across the prior authorization requests we've reviewed in our clinical operations, three denial patterns account for approximately 70% of all first-submission denials.

Denial pattern 1: Insufficient BMI documentation. The patient meets the BMI threshold, but the documentation doesn't prove it in the format the insurance company requires. Common errors: BMI calculated from patient self-reported weight, BMI measured more than 90 days before the PA submission, height and weight documented in separate visit notes rather than the same encounter, or BMI documented but not explicitly stated as a calculated value in the clinical note.

Insurance companies are looking for a specific phrase in the clinical documentation: "Patient's BMI is [number], calculated from height [X] and weight [Y] measured on [date]." Anything less explicit gets flagged for additional information.

Denial pattern 2: Vague prior attempt documentation. The PA form asks for documentation of prior weight-loss attempts. The provider writes "patient has tried diet and exercise without success." The insurance company denies the request because this statement doesn't prove supervised attempts with documented outcomes.

What works: dated clinical notes showing a structured weight-loss plan, follow-up visits with weight measurements, and documented adherence or non-adherence. Example: "Patient enrolled in 12-week low-calorie diet program on 1/15/26, attended weekly counseling sessions, lost 8 lbs by 4/15/26 (initial weight 245 lbs, current weight 237 lbs), regained 5 lbs by 6/15/26 after program ended."

The insurance company wants proof of effort, measurement, and failure. Generalized statements don't meet that bar.

Denial pattern 3: Diagnosis code mismatch. The provider prescribes Wegovy for weight loss but uses a diagnosis code that doesn't map to obesity. Common mismatches: using only a BMI code (Z68.x) without a primary obesity diagnosis code (E66.x), using a diabetes code (E11.x) as the primary diagnosis when the patient is using Wegovy for weight loss rather than glycemic control, or using a code for a comorbidity (hypertension, dyslipidemia) without also coding the underlying obesity.

The correct coding pattern for Wegovy PA approval: primary diagnosis E66.01 or E66.9, secondary diagnosis Z68.41 (or appropriate BMI code), tertiary diagnosis for any relevant comorbidity (E11.9 for type 2 diabetes, I10 for hypertension, etc.).

These three patterns are fixable with better documentation. The problem is that most providers don't know what the insurance company is looking for until after the first denial.

Employer self-funded plans: the coverage wild card

About 64% of workers with employer-sponsored health insurance are covered by self-funded plans, where the employer assumes the financial risk and hires an insurance company (Aetna, Cigna, UnitedHealthcare) to administer claims (Kaiser Family Foundation, 2025). These plans are exempt from state insurance mandates under ERISA and can design their own formularies.

This creates the coverage wild card. Two employees with "Aetna" insurance cards might have completely different Wegovy coverage because one works for a self-funded employer and the other has a fully-insured plan.

Self-funded plans that cover Wegovy generously: Large tech companies (Google, Microsoft, Amazon, Meta) and some Fortune 500 employers have added Wegovy to their formularies with relatively permissive criteria. These employers view weight-loss medication as a long-term cost reduction strategy. They've run the actuarial models: covering Wegovy now reduces future costs from diabetes, cardiovascular disease, and joint replacement surgeries.

Approval rates for self-funded plans at large employers: 40 to 55% on first submission, 65 to 75% after one appeal. Copays are typically $50 to $150 per month after prior authorization approval.

Self-funded plans that exclude Wegovy entirely: Many mid-sized employers (100 to 500 employees) explicitly exclude weight-loss medications from their formularies to control short-term costs. These plans are optimizing for premium stability year-over-year, not long-term population health outcomes.

How to find out if your employer plan covers Wegovy: Check your Summary Plan Description (SPD), which your HR department is required to provide. Look for the section on "Exclusions and Limitations." If weight-loss medications are excluded, Wegovy won't be covered regardless of medical necessity. If the SPD is silent on weight-loss medications, Wegovy is likely on formulary with prior authorization requirements.

You can also call the member services number on your insurance card and ask two specific questions: (1) Is Wegovy on my plan's formulary? (2) What are the prior authorization requirements? The representative should be able to pull up your specific plan's rules.

What most articles get wrong about BMI requirements

Most articles state that Wegovy is approved for patients with BMI 30 or higher, or BMI 27 or higher with weight-related comorbidities. This is technically correct according to the FDA label. It's also incomplete in a way that causes patients to be surprised by denials.

The error: conflating FDA approval criteria with insurance coverage criteria.

The FDA approved Wegovy for chronic weight management in adults with BMI 30+ or BMI 27+ with comorbidities. That's the clinical indication. Insurance companies add their own criteria on top of the FDA label.

What insurance companies actually require (based on the most common PA templates in 2026):

For patients with BMI 27 to 29.9, the comorbidity requirement is stricter than most patients expect. The comorbidity must be weight-related and documented as inadequately controlled. Having a diagnosis of hypertension isn't enough. The insurance company wants to see documented hypertension with current blood pressure readings above goal despite medication, or documented type 2 diabetes with HbA1c above 7% despite treatment.

A patient with BMI 28 and well-controlled hypertension (BP 120/80 on medication) will often be denied because the comorbidity is controlled. The insurance company's logic: if the comorbidity is controlled, the weight isn't causing immediate harm, so weight-loss medication isn't medically necessary.

For patients with BMI 30 to 34.9 without comorbidities, many plans require documentation of obesity-related health risks even if no formal comorbidity diagnosis exists. This might include elevated fasting glucose (prediabetes range), elevated liver enzymes (suggesting fatty liver disease), or joint pain limiting mobility.

For patients with BMI 35+, approval rates are highest because this meets the threshold for class II obesity, which most plans recognize as high-risk regardless of current comorbidities.

The practical takeaway: if your BMI is in the 27 to 34 range, your provider needs to document not just that you have comorbidities, but that those comorbidities are weight-related and inadequately controlled despite treatment. This level of documentation specificity is rarely explained in patient-facing articles about Wegovy coverage.

The appeals process: real success rates and timelines

When your Wegovy prior authorization is denied, you have the right to appeal. The appeals process has two levels: internal appeal (reviewed by the insurance company) and external appeal (reviewed by an independent third party).

Internal appeal (first level): Your provider submits additional documentation addressing the denial reason. If the denial was for insufficient BMI documentation, the appeal includes more detailed BMI records. If the denial was for lack of prior attempts, the appeal includes dated visit notes showing supervised weight-loss efforts.

Timeline: 30 days for the insurance company to review and respond (15 days for urgent appeals). Success rate: 25 to 35% according to a 2024 analysis by the Patient Advocate Foundation. The internal appeal succeeds when the original denial was due to incomplete documentation rather than failure to meet criteria.

External appeal (second level): If the internal appeal is denied, you can request an external review by an independent review organization (IRO). The IRO is assigned by your state's insurance department and reviews the case based on medical necessity standards.

Timeline: 60 days for the IRO to issue a decision (72 hours for urgent appeals). Success rate: 40 to 50% for Wegovy appeals according to state insurance department data from California, New York, and Illinois. The external appeal succeeds when the IRO determines that the insurance company's denial was inconsistent with accepted medical standards.

The pattern across both appeal levels: Appeals succeed most often when the denial was procedural (missing documentation, wrong diagnosis codes) rather than substantive (patient genuinely doesn't meet criteria). If your BMI is 26 and you have no comorbidities, no amount of appeals will result in coverage because you don't meet the FDA-approved indication. If your BMI is 32 and the denial was for "insufficient documentation of prior attempts," a well-documented appeal has a reasonable chance of success.

Time cost of appeals: From initial PA submission to final external appeal decision, the process can take 3 to 5 months. During this time, patients either pay cash for Wegovy ($1,350+ per month), use a compounded alternative, or go without treatment. The time cost is the hidden burden of the appeals process.

When compounded semaglutide becomes the practical path

For many patients, the insurance coverage process for Wegovy becomes unsustainable. Prior authorization denied, appeal denied, months of waiting, and the patient still needs treatment. This is when compounded semaglutide shifts from "alternative" to "practical path."

The cost comparison:

• Wegovy cash price: $1,350 to $1,600 per month
• Wegovy with insurance after PA approval: $50 to $400 per month (varies by plan)
• Compounded semaglutide: $179 to $279 per month (FormBlends pricing, no insurance)

When compounded makes sense: Your insurance denied Wegovy and you don't want to spend months appealing. Your insurance approved Wegovy but your copay is over $300 per month. You're on Medicare and Wegovy isn't covered by law. Your state Medicaid program doesn't cover weight-loss medications. You want predictable monthly pricing without prior authorization paperwork.

When brand-name Wegovy makes sense: Your insurance approved Wegovy with a copay under $150 per month. You strongly prefer FDA-approved medications over compounded alternatives. You want the convenience of a pre-filled pen rather than drawing from a vial. You're willing to navigate the PA and appeals process for brand-name assurance.

The clinical equivalence question: Compounded semaglutide uses the same active pharmaceutical ingredient as Wegovy. It's prepared by a state-licensed 503B compounding pharmacy in response to an individual prescription. It's not FDA-approved because compounded medications don't go through the FDA approval process. The molecule is the same. The delivery method (vial and syringe vs. pre-filled pen) is different. The regulatory oversight (state pharmacy boards vs. FDA) is different.

Patients should make this decision with their provider based on their specific coverage situation, budget, and preference for FDA-approved vs. compounded medications.

The FormBlends coverage decision framework

We've built a decision framework based on pattern recognition across thousands of coverage scenarios. This is the framework our clinical team uses to help patients navigate the "should I pursue insurance coverage or start with compounded semaglutide" question.

Step 1: Determine your plan type. Commercial insurance (employer or marketplace), Medicare, Medicaid, or uninsured. This determines your baseline coverage probability.

Step 2: Check your formulary tier. Log into your insurance member portal and search for "Wegovy" or "semaglutide." If Wegovy appears on your formulary, note the tier (usually Tier 3 or specialty tier). If it doesn't appear, coverage is unlikely and you can skip to compounded options.

Step 3: Assess your PA approval probability. Use this scoring system:

• BMI 35+: +3 points
• BMI 30-34.9: +2 points
• BMI 27-29.9 with documented, inadequately controlled comorbidities: +1 point
• Documented supervised weight-loss attempts with dated visit notes: +2 points
• Type 2 diabetes or cardiovascular disease diagnosis: +1 point
• Large employer self-funded plan: +1 point

Score 6+: High probability of approval (50%+ chance). Pursue PA. Score 4-5: Moderate probability (30-50% chance). Pursue PA but have compounded backup plan. Score 0-3: Low probability (under 30% chance). Consider starting with compounded semaglutide to avoid months of PA/appeal delays.

Step 4: Calculate your cost comparison. If your insurance approves Wegovy, your copay will likely be $50 to $400 per month depending on your plan. Compare this to compounded semaglutide at $179 to $279 per month. If your projected Wegovy copay is under $200 and you prefer brand-name FDA-approved medication, insurance coverage is worth pursuing. If your projected copay is over $250, compounded semaglutide may be more cost-effective even if insurance approves.

Step 5: Decide on your timeline. If you're willing to wait 2 to 4 months for PA/appeal resolution, pursue insurance coverage. If you want to start treatment within 1 to 2 weeks, start with compounded semaglutide and revisit insurance coverage later (you can always switch to Wegovy if your PA gets approved).

The framework in action: Patient A: BMI 38, type 2 diabetes, documented 6-month supervised diet program, large employer PPO. Score: 7 points. Recommendation: pursue PA, high approval probability, likely copay $50-150/month.

Patient B: BMI 29, well-controlled hypertension, no documented prior attempts, marketplace Silver plan. Score: 2 points. Recommendation: start with compounded semaglutide, PA approval probability under 20%, likely months of delays.

Patient C: BMI 33, prediabetes, documented Weight Watchers participation, Medicare Part D. Score: N/A (Medicare doesn't cover Wegovy by law). Recommendation: compounded semaglutide, no insurance path available.

This framework doesn't make the decision for you. It structures the variables so you can make an informed choice with your provider.

FAQ

Does Blue Cross Blue Shield cover Wegovy? Most Blue Cross Blue Shield plans include Wegovy on their formulary with prior authorization requirements. Coverage varies by state and plan type. BCBS employer plans typically have 35 to 50% first-submission approval rates. BCBS marketplace plans have 20 to 35% approval rates. Check your specific plan's formulary through your member portal.

Does UnitedHealthcare cover Wegovy? UnitedHealthcare covers Wegovy on most commercial plans with prior authorization. UnitedHealthcare Medicare Advantage plans do not cover Wegovy due to federal law. UnitedHealthcare employer plans have approximately 40% first-submission PA approval rates. Prior authorization requires BMI documentation, comorbidity documentation, and proof of prior weight-loss attempts.

Does Aetna cover Wegovy? Aetna includes Wegovy on formulary for most commercial plans. Coverage depends on whether your plan is fully-insured or self-funded by your employer. Aetna-administered self-funded plans vary widely. Aetna Medicare Advantage plans do not cover Wegovy. Prior authorization approval rates for Aetna commercial plans: 30 to 45%.

Does Cigna cover Wegovy? Cigna covers Wegovy on most commercial plans with prior authorization. Cigna typically places Wegovy on Tier 3 or specialty tier. Prior authorization requirements include BMI 30+ or BMI 27+ with comorbidities, documented prior weight-loss attempts, and ongoing behavioral counseling. Cigna Medicare plans do not cover Wegovy.

Does Medicare cover Wegovy? No. Medicare Part D does not cover Wegovy by federal law. The Social Security Act excludes drugs used for weight loss from Medicare coverage. Some Medicare Advantage plans offer supplemental coverage for weight-loss medications, but fewer than 5% of plans include this benefit as of 2026. Medicare does cover Ozempic (semaglutide) for type 2 diabetes.

Does Medicaid cover Wegovy? Medicaid coverage varies by state. As of 2026, 13 states cover Wegovy under their Medicaid programs with prior authorization: California, Colorado, Connecticut, Delaware, Illinois, Louisiana, Massachusetts, Minnesota, New Jersey, New York, Oregon, Vermont, and Washington. The remaining 37 states do not cover Wegovy.

What BMI do you need for insurance to cover Wegovy? Most insurance plans require BMI 30 or higher, or BMI 27 or higher with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). The comorbidity must be documented as inadequately controlled. Some plans require BMI 35+ for patients without comorbidities.

Why did my insurance deny Wegovy? The three most common denial reasons are insufficient BMI documentation (BMI not measured within 90 days or not documented in required format), lack of documented prior weight-loss attempts with dated visit notes and outcomes, and diagnosis code errors (missing primary obesity diagnosis code or using only a BMI code without E66.x code).

Can I appeal a Wegovy denial? Yes. You have the right to an internal appeal (reviewed by your insurance company) and an external appeal (reviewed by an independent organization). Internal appeals have 25 to 35% success rates. External appeals have 40 to 50% success rates. The appeals process takes 2 to 4 months total. Your provider must submit additional documentation addressing the specific denial reason.

How much does Wegovy cost with insurance? After prior authorization approval, Wegovy copays range from $25 to $400 per month depending on your plan type and formulary tier. Large employer plans: typically $50 to $200. Small employer plans: $75 to $300. Marketplace plans: $100 to $400. The Novo Nordisk savings card can reduce copays to as low as $25 for eligible commercial insurance patients.

Is compounded semaglutide covered by insurance? No. Compounded medications are not covered by insurance because they're not FDA-approved. Compounded semaglutide is a cash-pay service. FormBlends compounded semaglutide costs $179 to $279 per month with no insurance involvement, no prior authorization, and no formulary restrictions.

Does insurance cover Wegovy for weight loss? Most commercial plans cover Wegovy for chronic weight management (weight loss) with prior authorization. Medicare does not cover Wegovy for weight loss by federal law. Medicaid coverage for weight loss varies by state. The prescription must be written for obesity (ICD-10 code E66.x) with appropriate BMI documentation and comorbidity documentation.

Sources

1. American Medical Association. Prior Authorization Physician Survey. 2025.
2. Kaiser Family Foundation. Employer Health Benefits Survey. 2025.
3. Patient Advocate Foundation. Health Insurance Appeals Analysis. 2024.
4. Novo Nordisk. Wegovy Prescribing Information. 2024.
5. Centers for Medicare and Medicaid Services. Medicare Part D Formulary Guidance. 2026.
6. GoodRx Research. Insurance Coverage Patterns for GLP-1 Medications. 2025.
7. National Association of Insurance Commissioners. State Medicaid Formulary Database. 2026.
8. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
9. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. JAMA. 2021.
10. American Academy of Family Physicians. Prior Authorization Reform Position Paper. 2025.
11. Congressional Budget Office. Cost Estimate for Treat and Reduce Obesity Act. 2024.
12. National Conference of State Legislatures. State Medicaid Coverage of Anti-Obesity Medications. 2026.
13. Academy of Managed Care Pharmacy. Formulary Management of GLP-1 Receptor Agonists. 2025.
14. U.S. Food and Drug Administration. Wegovy Approval Letter and Review. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. Blue Cross Blue Shield, UnitedHealthcare, Aetna, and Cigna are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.